CervoMed Inc.

CervoMed Inc.

CRVO·NASDAQ

$5.50

-0.36%
HealthcareBiotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$50.89M
EPS-2.0200
P/E Ratio-1.16
Earnings Date03/16/2026

crvo

Net Common Stock Issuance

Last Annual Value

46.40M

3-Year CAGR

14%

5-Year CAGR

30%

10-Year CAGR

4%

CervoMed Inc.

CervoMed Inc. Competitors Analysis of Net Common Stock Issuance

CRVO · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
46.40M
285.5%8.3%N/A 
15.86M
25.0%-15.6%N/A
84.37M
1.6%-11.5%7.7%
5.23M
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
75.50M
480.5%-20.5%N/A
CLNN logo
Clene Inc.
NASDAQ:CLNN
10.40M
-37.2%2.4%N/A
6.03M
-31.0%-44.2%N/A
12.23M
157.5%-22.6%N/A
107.39M
89.8%41.9%N/A
505.00K
-75.7%-24.2%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
4.44M
-33.4%-48.5%N/A
CervoMed Inc.

CervoMed Inc. Fair Value Envelope

CRVO · NASDAQ

Our analysis suggests that CRVO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.5, this represents a potential HIDDEN relative to our calculated worth for CervoMed Inc..

Intrinsic Value
Current Price: $5.5